EpiVax Inc, a US-based biotechnology company, has revealed an update on the progress of its peptide therapeutic immunogenicity assessment programme, it was reported on Tuesday.
The programme was initially developed for screening generic peptide drugs and their impurities following the publication of ANDA draft guidance by US Food and Drug Administration. The company performed validation studies of the in silico tools and in vitro validation methods used in the Peptide Abbreviated New Drug Application programme in collaboration with CUBRC.
The company's peptide immunogenicity screening services have increased, now providing around twenty% of its total revenue between 2017 and 2020 in its contracted Peptide Abbreviated New Drug Application peptide immunogenicity research.
Newbury Pharmaceuticals gains Danish approval for generic ivermectin cream
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Zentiva announces sale from Advent to GTCR
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval
Newbury Pharmaceuticals gains Finnish approval for generic melatonin
CivicaScript to distribute biosimilar for chronic inflammatory conditions
Mallinckrodt and Endo complete merger
Zenara Pharma's Sertraline Hydrochloride Capsules generic receives US FDA approval